These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26475495)

  • 1. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.
    Heck A; Emblem KE; Casar-Borota O; Bollerslev J; Ringstad G
    Endocrine; 2016 May; 52(2):333-43. PubMed ID: 26475495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
    Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
    Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
    Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
    Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
    Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.
    Shen M; Zhang Q; Liu W; Wang M; Zhu J; Ma Z; He W; Li S; Shou X; Li Y; Zhang Z; Ye H; He M; Lu B; Yao Z; Lu Y; Qiao N; Ye Z; Zhang Y; Yang Y; Zhao Y; Wang Y
    Neuroradiology; 2016 Nov; 58(11):1057-1065. PubMed ID: 27516099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas.
    Tortora F; Negro A; Grasso LFS; Colao A; Pivonello R; Splendiani A; Brunese L; Caranci F
    Gland Surg; 2019 Sep; 8(Suppl 3):S150-S158. PubMed ID: 31559182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly.
    Heck A; Emblem KE; Casar-Borota O; Ringstad G; Bollerslev J
    Endocrine; 2016 Jul; 53(1):327-30. PubMed ID: 26615593
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
    Ilie MD; Tabarin A; Vasiljevic A; Bonneville JF; Moreau-Grangé L; Schillo F; Delemer B; Barlier A; Figarella-Branger D; Bisot-Locard S; Santos A; Chanson P; Raverot G
    J Clin Endocrinol Metab; 2022 Nov; 107(11):2982-2991. PubMed ID: 36136828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI.
    Kocak B; Durmaz ES; Kadioglu P; Polat Korkmaz O; Comunoglu N; Tanriover N; Kocer N; Islak C; Kizilkilic O
    Eur Radiol; 2019 Jun; 29(6):2731-2739. PubMed ID: 30506213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.
    Potorac I; Beckers A; Bonneville JF
    Pituitary; 2017 Feb; 20(1):116-120. PubMed ID: 28197813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
    Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Diffusion-Weighted and T2-Weighted Imaging in the Prediction of Distinct Granulation Patterns of Somatotroph Adenomas.
    Tang Y; Xie T; Guo Y; Liu S; Li C; Liu T; Zhao P; Yang L; Li Z; Yang H; Zhang X
    World Neurosurg; 2024 Feb; 182():e334-e343. PubMed ID: 38052365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
    Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
    Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T2-weighted magnetic resonance imaging as a novel predictor of surgical remission in newly diagnosed pituitary macroadenomas presenting as acromegaly.
    Akkaya E; Akgun MY; Sebnem Durmaz E; Aydın S; Mefkure Ozkaya H; Comunoglu N; Kizilkilic O; Gazioglu N; Kadioglu P; Tanriover N
    J Clin Neurosci; 2021 Aug; 90():105-111. PubMed ID: 34275532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.
    Swanson AA; Erickson D; Donegan DM; Jenkins SM; Van Gompel JJ; Atkinson JLD; Erickson BJ; Giannini C
    Pituitary; 2021 Apr; 24(2):192-206. PubMed ID: 33074402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Added Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Response to Somatostatin Analogs in Acromegaly Patients.
    Durmaz ES; Kocak B; Kadioglu P; Comunoglu N; Ulu MO; Kocer N; Islak C; Kizilkilic O
    Turk Neurosurg; 2019; 29(6):835-842. PubMed ID: 30900736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
    Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
    Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
    Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
    Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly.
    Fougner SL; Casar-Borota O; Heck A; Berg JP; Bollerslev J
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):96-102. PubMed ID: 21722151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly.
    Varlamov EV; Wood MD; Netto JP; Thiessen J; Kim J; Lim DST; Yedinak CG; Banskota S; Cetas JS; Fleseriu M
    Pituitary; 2020 Dec; 23(6):672-680. PubMed ID: 32870441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.